Topline data from interim 36-week proteinuria endpoint on track for first quarter of 2021
New name reflects dedication to patient- inspired mission of identifying, developing and delivering life-changing rare disease therapies
Addition of OT-58 strengthens pipeline of potential first-in-class therapies targeting rare diseases
SAN DIEGO, Nov. 11, 2020 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) today announced that Company management will present at the following upcoming virtual investor conferences in November and...
Pivotal DUPLEX Study of sparsentan in FSGS nears completion of enrollment; topline proteinuria data expected 1Q21
Agreement a dd s OT-58, a novel enzyme replacement therapy in Phase 1/2 development for the treatment of classical homocystinuria
SAN DIEGO, Oct. 21, 2020 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) today announced it will report third quarter 2020 financial results on Thursday, November 5, 2020 after the close of the U.S....
SAN DIEGO, Oct. 14, 2020 (GLOBE NEWSWIRE) -- Retrophin, Inc. (Nasdaq: RTRX) today announced that on October 10, 2020, the Compensation Committee of its Board of Directors granted inducement equity grants...
SAN DIEGO, Oct. 09, 2020 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) today announced that it will present new data from a post-hoc analysis examining the proportion of patients with focal segmental...
Topline data from 36-week proteinuria endpoint anticipated in third quarter of 2021